Tender detail
Non-exclusive medicine rebate agreements for certolizumab pegol under an Open House model
Summary
The procurement concerns non-exclusive rebate agreements for medicines containing the active ingredient certolizumab pegol (ATC code L04AB05), concluded under an Open House model pursuant to Section 130a(8) of SGB V. The quantity purchased is unknown and no minimum purchase volume is guaranteed. Agreements will end no later than 30 June 2028.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.